112913-94-7

Basic information

• Product Name: 2-Acetylamidomethyl-4-(4-fluorobenzyl)morpholine
• Synonyms: 2-Acetylamidomethyl-4-(4-fluorobenzyl)morpholine;N-((4-(4-Fluorobenzyl)Morpholin-2-yl)Methyl)acetaMide;N-((4-(4-Fluorobenzyl);N-[[4-[(4-fluorophenyl)methyl]morpholin-2-yl]methyl]acetamide
• CAS NO: 112913-94-7
• Molecular Formula: C₁₄H₁₉FN₂O₂
• Molecular Weight: 266.3112632
• EINECS: -0
• Product Categories: Pharmaceutical Intermediates
• Mol File: 112913-94-7.mol
• Article Data: 3

Chemical Properties

• Melting Point: 120-122 °C
• Boiling Point: 429.984 °C at 760 mmHg
• Flash Point: 213.847 °C
• Appearance: /
• Density: 1.152
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.521
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 15.80±0.46(Predicted)
• CAS DataBase Reference: 2-Acetylamidomethyl-4-(4-fluorobenzyl)morpholine(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Acetylamidomethyl-4-(4-fluorobenzyl)morpholine(112913-94-7)
• EPA Substance Registry System: 2-Acetylamidomethyl-4-(4-fluorobenzyl)morpholine(112913-94-7)

Safety Data

• Hazardous Substances Data: 112913-94-7(Hazardous Substances Data)

Usage

General Description

2-Acetylamidomethyl-4-(4-fluorobenzyl)morpholine is a chemical compound that belongs to the class of morpholine derivatives. It is a synthetic intermediate used in the production of pharmaceuticals and agrochemicals. 2-Acetylamidomethyl-4-(4-fluorobenzyl)morpholine has potential biological activity and is used as a building block in the synthesis of various drugs. It possesses an acetyl group, an amide group, and a benzyl group, showing potential for interacting with various biological targets. Additionally, its morpholine ring structure makes it suitable for drug design and discovery. The presence of a fluorobenzyl group adds to the chemical's unique properties, making it a useful tool in medicinal chemistry research and drug development.

InChI:InChI=1/C14H19FN2O2/c1-11(18)16-8-14-10-17(6-7-19-14)9-12-2-4-13(15)5-3-12/h2-5,14H,6-10H2,1H3,(H,16,18)

Upstream product

• 112913-95-8 2-(N-acetylaminomethyl)morpholine 
• 352-11-4 1-chloromethyl-4-fluorobenzene 
• 112913-96-9 2-(N-acetylaminomethyl)-4-benzylmorpholine 
• 22116-33-2 2-(4-fluoro-benzyl-amino)-ethanol 
• 131322-23-1 <2-(acetylamino)methyl>morpholine acetyl salt 
• 108-24-7 acetic anhydride 
• 112914-13-3 2-aminomethyl-4-(4-fluoro-benzyl) morpholine 

Downstream Products

• 131322-34-4 5-Chloro-2-ethoxy-N-[4-(4-fluoro-benzyl)-morpholin-2-ylmethyl]-4-formylamino-benzamide 
• 112885-41-3 mosapride 
• 112885-34-4 4-acetylamino-5-chloro-2-ethoxy-N-[[4-(4-fluorobenzyl)-2-morpholinyl]methyl]benzamide 
• 112885-17-3 4-Amino-5-chloro-N-[4-(4-fluoro-benzyl)-morpholin-2-ylmethyl]-2-methoxy-benzamide 
• 112914-13-3 2-aminomethyl-4-(4-fluoro-benzyl) morpholine 

Relevant articles and documents

Synthesis and biological activity of 4-amino-5-chloro-2-ethoxy-3- hydroxybenzamides, metabolites of a new gastroprokinetic agent, mosapride

To confirm the proposed structures of the minor metabolites of a potential gastroprokinetic agent, mosapride, 4-amino-5-chloro-2-ethoxy-3- hydroxy-N-(2-morpholinylmethyl)benzamide (3) and the N-(5-oxo-2- morpholinyl)methyl analogue 4 were prepared. As the

Substituted benzamide derivatives, for enhancing gastrointestinal motility

Compounds of the formula: STR1 wherein R is hydrogen, alkoxycarbonyl, benzyloxycarbonyl, heteroarylalkyl, phenylalkenyl, or --T--(Y)p --R6 (wherein T is single bond or alkylene, Y is oxygen, sulfur or carbonyl, R6 is phenyl, substituted phenyl, naphthyl, or diphenylmethyl, and p is 0 or 1, provided that when T is single bond, p is 0); R1 is halogen, hydroxy, alkoxy, cycloalkyloxy, alkenyloxy, alkynyloxy, alkoxy interrupted by oxygen or carbonyl, alkylthio, amino, monosubstituted amino, or a substituted alkoxy; R2 is hydrogen; R3 is hydrogen, halogen, amino, alkylamino, dialkylamino, alkanoylamino, or nitro; R4 is hydrogen, halogen, nitro, sulfamoyl, alkylsulfamoyl, or dialkylsulfamoyl; or any two adjacent groups of the R1, R2, R3 and R4 may combine to form alkylenedioxy, and the remaining two groups are each hydrogen; R5 is hydrogen or alkyl; X is alkylene; m and n are each 1 or 2; provided that at least one of the groups R2, R3 and R4 is other than hydrogen, and acid addition salts, quaternary ammonium salts and N-oxide derivatives thereof, processes for preparation thereof, and pharmaceutical composition containing the same. Said compounds, salts and N-oxide derivatives thereof show excellent gastrointestinal motility enhancing activity.